SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Summit Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$15.57+0.94 (+6.43%)
Close on Oct 19, 2026
- Market cap
- $12.12B
- P/E (TTM)
- –
- Dividend yield
- –
Summit Therapeutics Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Licensing agreements | – | – | – | $705.00K | $1.81M | $56.76M | – | – |
| Research collaboration agreement | – | – | – | – | – | $327.00K | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Europe | – | – | – | – | – | $327.00K | – | – |
| Latin America | – | – | – | $705.00K | $1.81M | $662.00K | – | – |
| United States | – | – | – | – | $0 | $56.10M | – | – |
From the segment and revenue-disaggregation notes of Summit Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.